Final report of phase I clinical, pharmacokinetic (PK), pharmacodynamic (PD) study of PF-00562271 targeting focal adhesion kinase (FAK) in patients (pts) with solid tumors. A phase I dose-escalation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results